Archive for 2012
May 16th, 2012
Study Question:
What is the relative value of bariatric surgery compared to medical therapy for glycemic control in type 2 diabetes mellitus?
Methods:
STAMPEDE was a randomized controlled single-center trial comparing the efficacy of intensive medical therapy alone versus medical therapy plus Roux-en-Y gastric bypass or sleeve gastrectomy in 150 obese patients with uncontrolled type 2 diabetes. All patients were treated with lipid-lowering and antihypertensive medications with target systolic blood pressure ≤130 mm Hg, diastolic blood pressure ≤80 mm Hg, and low-density lipoprotein cholesterol ≤100 mg/dl. The primary endpoint
May 15th, 2012
Highlights how Codexis platform enables breakthrough biocatalytic processes
REDWOOD CITY, Calif.--(CRWENewswire)--Codexis, Inc. (Nasdaq:CDXS), a developer of cost-advantaged processes for the production of biofuels, bio-based chemicals, and pharmaceutical intermediates, today announced that the United States Patent and Trademark Office (USPTO) has granted Codexis’ patent covering the biocatalysts and biocatalytic processes used to make key pharmaceutical intermediates in the synthesis of leading hepatitis-C therapeutics.
The patent is titled “BIOCATALYTIC PROCESSES FOR THE PREPARATION OF SUBSTANTIALLY STEREOMERICALLY PURE FUSED BICY
May 15th, 2012
NEW YORK, May 15, 2012 (CRWENewswire)-- Capital Trust, Inc. (NYSE:CT) (the "Company") announced today that its Board of Directors (the "Board") has formed a Special Committee of the Board comprised of independent directors (the "Special Committee") to consider and explore strategic alternatives available to the Company in order to maximize shareholder value. The Special Committee intends to undertake a thorough exploration of the full range of alternatives, including a possible sale of the Company and has retained Evercore Partners to serve as its financial advisor.
No decision has been made to engage in a transaction or transactions res
May 15th, 2012
The FDA recently approved Prevnar 13® for use in adults aged 50 years and older for the prevention of pneumonia and invasive disease caused by the serotypes included in the vaccine.
The most common clinical presentation of pneumococcal disease PD in adults is pneumococcal pneumonia.1 PD is a leading cause of vaccine-preventable death in the United States and is a major cause of pneumonia, bacteremia, and meningitis.2
PD is a serious disease with serious consequences in adults and is associated with significant morbidity.3
Still, the impact of PD is often underestimated, particularly in the 50+ population.
Help protect your patien
May 14th, 2012
A neuropsychological test captures the episodic memory deficit associated with AD, even early in the disease process.
Relatively brief and easy-to-perform neuropsychological tests that are valid and sensitive are important clinical tools for diagnosing specific dementias. A research group recently reported on a measure for Alzheimer disease (AD) — the Free and Cued Selective Reminding Test (FCSRT). Two other common standard neuropsychological tests were also given (CERAD neuropsychological battery and paragraph recall from the Wechsler Memory Scale).
The 185 participants had mild cognitive impairment (MCI; scores, >1 standard deviatio
May 14th, 2012
HOUSTON, May 14, 2012 (CRWENewswire) -- FMC Technologies, Inc. (NYSE:FTI) announced today that it has signed an agreement with Technip France, on behalf of the Technip Samsung Consortium (TSC), to supply offshore loading arm systems as part of the Shell Prelude Floating Liquefied Natural Gas (FLNG) Project.
FMC's scope of supply includes seven offshore footless marine loading arms, four for liquefied natural gas and three for liquefied petroleum gas. FMC's Loading Systems business in Sens, France will design and manufacture the equipment.
"Today's announcement expands our existing support of the Prelude development, having received the subs
May 14th, 2012
BEIJING, May 14, 2012 (CRWENewswire) -- China Shen Zhou Mining & Resources, Inc. ("China Shen Zhou" or the "Company") (Amex:SHZ), a Company engaged in the exploration, development, mining and processing of fluorite, barite, zinc, copper, and other nonferrous metals in China, today announced that the Keyinbulake Mine of Xingzhen, a subsidiary of China Shen Zhou located in Buerjin County, Aletai District, Xinjiang Uygur Autonomous Region, has received positive feedback on the production of non-ferrous metals.
China Shen Zhou made positive progress after a few years exploring and prospecting the Keyinbulake Mine. Starting in the second qua
May 13th, 2012
ORLANDO, Fla., May 11, 2012 (CRWENewswire Fri, May 11, 2012) -- Gencor Industries, Inc., (Nasdaq:GENC) announced today that revenue for the second quarter ended March 31, 2012 increased 16% to $19.3 million from $16.7 million for the quarter ended March 31, 2011. Gross margin as a percentage of revenues increased to 21.0% for the quarter ended March 31, 2012 from 16.0% for the quarter ended March 31, 2011. Operating income for the quarter ended March 31, 2012 was $1.0 million compared to a $0.2 million operating loss for the quarter ended March 31, 2011.
The Company had non-operating, net investment income of $3.2 million for the quarter
May 12th, 2012
PORT TOWNSEND, Wash.--(CRWENewswire - Fri, May 11, 2012)--Intellicheck Mobilisa, Inc. (NYSE Amex: IDN), a leading technology company specializing in wireless and identity systems, announced today that a seaport has purchased the Company’s IM2700 mobile Transportation Worker Identity Credential (TWIC) reader system. The contract, valued at $1 million, is the largest single TWIC sale in the Company’s history.
Steve Williams, Chief Executive Officer of Intellicheck Mobilisa, said, “This is the largest TWIC sale we have made to one facility and a market we’ve been creating and leading. The port wanted to increase their security effor
May 12th, 2012
– Final FDA Decision On The Quad Anticipated Late Summer –
FOSTER CITY, Calif.--(CRWENewswire - Friday May 11, 2012)--Gilead Sciences, Inc. (Nasdaq: GILD) today announced that the Antiviral Drugs Advisory Committee of the U.S. Food and Drug Administration (FDA) has voted 13 to 1 in support of approval of the Quad, a complete single tablet regimen of elvitegravir, cobicistat, emtricitabine and tenofovir disoproxil fumarate, for the treatment of HIV-1 infection in treatment-naĂŻve adults.
The recommendations of the Advisory Committee are not binding, but will be considered by FDA as the agency completes its review of Gilead’s New Dr
